Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Benidipine is a synthetic dihydropyridine calcium channel blocker primarily used for the treatment of hypertension and angina pectoris. It acts as a triple calcium channel inhibitor by blocking L-type, N-type, and T-type voltage-dependent calcium channels. This broad inhibition leads to vasodilation and reduced blood pressure. In addition to its antihypertensive effects, benidipine exhibits cardioprotective and renoprotective properties—partly through stimulation of nitric oxide production and suppression of vascular smooth muscle proliferation. Notably, it also functions as an antagonist of the mineralocorticoid receptor (antimineralocorticoid), contributing further to its cardiovascular benefits. Developed in Japan by Kyowa Hakko (now Kyowa Kirin), it is marketed in several Asian countries including Japan and India[1][5][6][7][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on benidipine.